Welcome to our dedicated page for Lifemd SEC filings (Ticker: LFMDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeMD, Inc. filings document the formal disclosures for the virtual primary care company and its listed securities, including common stock and the 8.875% Series A Cumulative Perpetual Preferred Stock. Form 8-K reports cover operating results, financial condition, earnings guidance, Regulation FD investor presentations, and executive officer changes.
Definitive proxy materials describe annual meeting procedures, board and governance matters, compensation-related disclosures, and stockholder voting items. The filing record also identifies the preferred security within the company's capital structure, including matters relevant to LFMDP holders such as preferred-stock status and related public-company disclosures.
Kavthekar Atul reported acquisition or exercise transactions in this Form 4 filing.
LifeMD, Inc. reported that its Chief Financial Officer, Atul Kavthekar, received a grant of 337,500 shares of Common Stock in the form of restricted stock units. The award was recorded at a price of $0.00 per share, reflecting a compensation grant rather than a market purchase.
Following this grant, Kavthekar directly holds 337,500 shares. The units vest over time: 112,500 shares on March 16, 2027, another 112,500 shares on March 16, 2028, and the remaining portion on March 16, 2029, aligning his compensation with multi‑year service.
Kavthekar Atul reported acquisition or exercise transactions in this Form 4 filing.
LifeMD, Inc. reported that its Chief Financial Officer, Atul Kavthekar, received a grant of 337,500 shares of Common Stock in the form of restricted stock units. The award was recorded at a price of $0.00 per share, reflecting a compensation grant rather than a market purchase.
Following this grant, Kavthekar directly holds 337,500 shares. The units vest over time: 112,500 shares on March 16, 2027, another 112,500 shares on March 16, 2028, and the remaining portion on March 16, 2029, aligning his compensation with multi‑year service.
LifeMD, Inc. has issued its 2026 proxy statement for a virtual annual meeting on June 12, 2026, asking stockholders to elect seven directors, ratify PricewaterhouseCoopers as auditor, approve changes to its equity plan, and authorize possible adjournment of the meeting.
The Fourth Amended and Restated 2020 Equity and Incentive Plan would add 3,000,000 shares, remove the evergreen annual share increase, tighten share-counting rules, and prohibit option repricing without stockholder approval. The filing also describes a “little r” restatement-driven clawback of 392,000 shares of performance stock, valued at $1,336,720, and notes that 2025 formula bonuses under the corporate plan paid out at 0%, with the CEO’s 2025 total compensation at $777,075.
LifeMD, Inc. has issued its 2026 proxy statement for a virtual annual meeting on June 12, 2026, asking stockholders to elect seven directors, ratify PricewaterhouseCoopers as auditor, approve changes to its equity plan, and authorize possible adjournment of the meeting.
The Fourth Amended and Restated 2020 Equity and Incentive Plan would add 3,000,000 shares, remove the evergreen annual share increase, tighten share-counting rules, and prohibit option repricing without stockholder approval. The filing also describes a “little r” restatement-driven clawback of 392,000 shares of performance stock, valued at $1,336,720, and notes that 2025 formula bonuses under the corporate plan paid out at 0%, with the CEO’s 2025 total compensation at $777,075.
Pisano Christopher A reported acquisition or exercise transactions in this Form 4 filing.
LifeMD, Inc. reported that Chief Marketing Officer Christopher A. Pisano received a grant of 200,000 shares of common stock in the form of restricted stock units on March 30, 2026. The award carries no purchase price.
According to the vesting terms, 50,000 units vest on the grant date, and an additional 50,000 units also vest on the grant dateMarch 30, 2027. A further 50,000 units vest on March 30, 2027, with the remaining units vesting on March 30, 2028, aligning the compensation with continued service at the company.
Pisano Christopher A reported acquisition or exercise transactions in this Form 4 filing.
LifeMD, Inc. reported that Chief Marketing Officer Christopher A. Pisano received a grant of 200,000 shares of common stock in the form of restricted stock units on March 30, 2026. The award carries no purchase price.
According to the vesting terms, 50,000 units vest on the grant date, and an additional 50,000 units also vest on the grant dateMarch 30, 2027. A further 50,000 units vest on March 30, 2027, with the remaining units vesting on March 30, 2028, aligning the compensation with continued service at the company.
LifeMD, Inc. executive Christopher A. Pisano, the company’s Chief Marketing Officer, filed an initial Form 3 as a reporting person. The filing lists no transactions or holdings, serving as a baseline disclosure of his status as an officer subject to insider reporting rules.
LifeMD, Inc. executive Christopher A. Pisano, the company’s Chief Marketing Officer, filed an initial Form 3 as a reporting person. The filing lists no transactions or holdings, serving as a baseline disclosure of his status as an officer subject to insider reporting rules.
LifeMD, Inc. filed an initial insider ownership report on SEC Form 3 for Atul Kavthekar, who serves as Chief Financial Officer. The filing identifies him as a reporting person but shows no buy, sell, exercise, gift, tax-withholding, or other transactions, with all transaction counts and share totals at zero in this excerpt.
LifeMD, Inc. filed an initial insider ownership report on SEC Form 3 for Atul Kavthekar, who serves as Chief Financial Officer. The filing identifies him as a reporting person but shows no buy, sell, exercise, gift, tax-withholding, or other transactions, with all transaction counts and share totals at zero in this excerpt.
LifeMD, Inc. announced a planned Chief Financial Officer transition, with current CFO Marc Benathen departing to pursue a new opportunity and remaining through March 31, 2026 to support an orderly handover. He will then provide transition advisory services for six to twelve months for a $38,117 monthly fee and receive COBRA reimbursement through no later than April 1, 2027, while forfeiting any RSUs unvested as of March 31, 2026.
The company appointed Atul Kavthekar as its new CFO effective March 16, 2026, with a base salary of $500,000 and an annual performance bonus targeted at 50% of base salary. As a material employment inducement, he will receive 675,000 RSUs, split evenly between time-based vesting over three years and performance-based vesting tied to company targets.
LifeMD also expanded its leadership team by promoting Chris Pisano to Chief Marketing Officer and Jessica Friedeman to Chief Business Officer, reflecting a broader effort to align finance, marketing, and business development with the company’s next phase of growth.
LifeMD, Inc. announced a planned Chief Financial Officer transition, with current CFO Marc Benathen departing to pursue a new opportunity and remaining through March 31, 2026 to support an orderly handover. He will then provide transition advisory services for six to twelve months for a $38,117 monthly fee and receive COBRA reimbursement through no later than April 1, 2027, while forfeiting any RSUs unvested as of March 31, 2026.
The company appointed Atul Kavthekar as its new CFO effective March 16, 2026, with a base salary of $500,000 and an annual performance bonus targeted at 50% of base salary. As a material employment inducement, he will receive 675,000 RSUs, split evenly between time-based vesting over three years and performance-based vesting tied to company targets.
LifeMD also expanded its leadership team by promoting Chris Pisano to Chief Marketing Officer and Jessica Friedeman to Chief Business Officer, reflecting a broader effort to align finance, marketing, and business development with the company’s next phase of growth.
LifeMD, Inc. reported strong 2025 growth, with full-year revenue up 25% to $194.1 million and adjusted EBITDA up 309% to $15.3 million. Fourth-quarter revenue rose 4% to $46.9 million, while adjusted EBITDA increased to $4.8 million, reflecting an 87% gross margin.
The business from continuing operations still posted a 2025 GAAP net loss of $10.2 million, but total net income reached $15.6 million including discontinued operations. LifeMD ended 2025 with $36.8 million in cash and no debt, supporting investment in GLP-1 weight management, Wegovy launches, and expanding women’s health offerings.
For 2026, LifeMD guides to revenue of $220–$230 million and adjusted EBITDA of $12–$17 million, with annualized run-rate revenue expected to exceed $250 million and run-rate adjusted EBITDA to exceed $25 million by Q4 2026.
LifeMD, Inc. reported strong 2025 growth, with full-year revenue up 25% to $194.1 million and adjusted EBITDA up 309% to $15.3 million. Fourth-quarter revenue rose 4% to $46.9 million, while adjusted EBITDA increased to $4.8 million, reflecting an 87% gross margin.
The business from continuing operations still posted a 2025 GAAP net loss of $10.2 million, but total net income reached $15.6 million including discontinued operations. LifeMD ended 2025 with $36.8 million in cash and no debt, supporting investment in GLP-1 weight management, Wegovy launches, and expanding women’s health offerings.
For 2026, LifeMD guides to revenue of $220–$230 million and adjusted EBITDA of $12–$17 million, with annualized run-rate revenue expected to exceed $250 million and run-rate adjusted EBITDA to exceed $25 million by Q4 2026.
Form 144 notice for proposed sale of securities. The filer intends to sell 75,000 common shares of the issuer through Charles Schwab (3000 Schwab Way, Westlake, TX) on 09/10/2025 on NASDAQ, with an aggregate market value of $459,000. The issuer has 47,417,393 shares outstanding. The 75,000 shares were acquired by RSU vesting from the issuer on 03/01/2025. No securities were sold by the selling person during the past three months. The notice includes the seller's representation that they possess no undisclosed material adverse information.